Novo Nordisk Sets Sights on Longevity Market as Wegovy Pill Surpasses Three Million Prescriptions

Novo Nordisk is preparing to venture far beyond its traditional weight-loss franchise. Chief executive Mike Doustdar, speaking at the American Diabetes Association meeting in New Orleans, confirmed the Danish drugmaker is actively exploring anti-aging research and aesthetic medicine as future growth engines. When asked about potential investments in skin care or hair-loss treatments, his answer was unequivocal: “Yes.” The message is clear — weight reduction may soon become just one component of a much broader therapeutic platform.

The pivot is underpinned by fresh clinical evidence. Researchers at the same conference presented data showing that semaglutide can reduce the biological age of the heart and kidneys, leading to a measurable drop in mortality risk. Crucially, these protective effects appear independent of the drug’s weight-loss action and often emerge before patients shed significant pounds. Novo Nordisk is now urging its scientists to identify additional indications for next-generation GLP-1 therapies, turning the pipeline into a potential launchpad for age-related disease management.

While the long-term vision unfolds, the company’s current blockbuster — the oral Wegovy pill — is already rewriting the rulebook on product launches. The tablet, which debuted in the US in January 2026 at a 25?mg dose, crossed the three?million?prescription mark in just over five months. The pace places it among the fastest?growing pharmaceutical rollouts in recent US history. More striking is the customer profile: more than 80% of new prescriptions are going to patients who had never used a GLP?1 therapy before, suggesting the pill is expanding the addressable market rather than merely cannibalising existing injections.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The commercial momentum has not, however, translated into share?price gains. Novo Nordisk stock fetched €36.97 on Monday, down 0.82% from Friday’s close and 17.27% lower since the start of the year. Over twelve months the decline deepens to 44.00%, leaving the equity far from its 52?week high of €70.13. While the shares currently trade 2.96% above the 50?day moving average, they sit 11.17% below the 200?day line, and the relative?strength index of 46.5 signals a neutral near?term posture. The market, it seems, wants more than encouraging product data.

Behind the headline sales figures, the pipeline is firing on multiple fronts. At the ADA Scientific Sessions (5–8?June 2026), Novo Nordisk unveiled analyses from the SELECT, STEP, ESSENCE and OASIS trials, showing that semaglutide reduces obstructive sleep apnoea, asthma?related events and systolic blood pressure in overweight patients with comorbidities. The experimental agent Zenagamtide — also known as Amycretin, a dual GLP?1/amylin receptor agonist — achieved a significant drop in A1C among adults with type?2 diabetes and produced weight loss of up to 14.6%. The company plans to advance the candidate into phase?3. Meanwhile, the CagriSema programme (2.4?mg/2.4?mg) delivered strong reductions in HbA1c and body weight across multiple studies.

International expansion of the Wegovy pill is gathering pace. On 3?June 2026, the tablet reached its first market outside the US — the United Arab Emirates. The region is becoming a strategic hub: on 22?May, the Emirates Drug Establishment welcomed Novo Nordisk’s decision to build a regional distribution centre, one of three planned global hubs, alongside a scientific office and a talent programme for Emirati nationals. The company intends to launch the pill in Europe and other regions during the second half of 2026.

Investors will get their next chance to gauge the financial impact on 5?August, when Novo Nordisk reports half?year results. The earnings call will likely focus on how quickly prescription growth for the oral therapy is flowing through to revenue. A more detailed strategic update is scheduled for the Capital Markets Day on 21?September, where management must make the global rollout, manufacturing plans and the next GLP?1 generation tangible in financial terms. For now, the stock remains stuck in a neutral band, waiting for proof that the operational story can finally lift its weight.

Ad

Novo Nordisk Stock: New Analysis - 8 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69500062 |